drugset / Trial / NCT04962022

Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants

NCT04962022

Phase 1 Completed 12 enrolled Pfizer
Non-randomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of PF-07321332/ritonavir in healthy participants.

Timeline

Start
2021-07-20
Primary completion
2021-09-30
Completion
2021-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule Oral
Subject Nirmatrelvir Small molecule Oral
Subject Ritonavir Other / unclassified Oral

Indications

No indication recorded.